Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
2/7/25 | Novo Nordisk (NVO) | Mim8 for Hemophilia A | Subscribers Only | Subscribers Only | Subscribers Only |
2/5/25 | Revalesio | RNS60 for Ischemic Stroke | Subscribers Only | Subscribers Only | Subscribers Only |
2/4/25 | Cumberland Pharmaceuticals (CPIX) | Ifetroban, Cumberland Pharmaceuticals for Duchenne Muscular Dystrophy (DMD) | Subscribers Only | Subscribers Only | Subscribers Only |
2/4/25 | LEO | Anzupgo for Atopic Dermatitis (Eczema) | Subscribers Only | Subscribers Only | Subscribers Only |
2/3/25 | GH Research (GHRS) | GH001 for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
02/05/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/06/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/06/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/06/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
02/06/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |